Introducing
DecisionDx® DiffDx™-Melanoma
Introducing DecisionDx® DiffDx™-Melanoma
A Highly Accurate and Objective Genomic Test
DiffDx-Melanoma is a new gene expression profile test to aid dermatopathologists in characterizing difficult-to-diagnose melanocytic lesions by providing a highly accurate, objective result. DiffDx-Melanoma can add to diagnostic clarity and provide confidence to dermatopathologists while helping dermatologists deliver more informed patient management plans.
Difficult-to-Diagnose Melanocytic Lesions Are a Problem
It is estimated that there are over 2 million biopsies of suspected melanoma annually in the U.S., leading to:
0
Over 130,000 invasive malignant melanomas
0
Nearly 96,000 diagnoses of melanoma in situ
0
Up to 300,000 lesions that cannot be confidently diagnosed with a routine H&E